Cartalax is a synthetic ultrashort tripeptide bioregulator (sequence: Ala-Glu-Asp) widely examined in laboratory settings for its influence on gene expression patterns and cellular processes specific to connective tissue and cartilage systems. This peptide draws from motifs identified in structural proteins such as collagen, supporting studies on tissue-specific bioregulation, matrix integrity, and senescence-related pathways.
Manufactured under GMP-aligned protocols, Cartalax arrives as lyophilized powder with comprehensive quality verification, including structural confirmation, purity analysis, and a complete third-party Certificate of Analysis (CoA) for each batch to ensure experimental consistency and traceability.
Key Scientific Features
- ≥98% purity verified through reverse-phase HPLC and mass spectrometry.
- Confirmed sequence: Ala-Glu-Asp (AED; C₁₂H₁₉N₃O₈, molecular weight 333.29 g/mol).
- Lyophilized format designed for maximum stability and straightforward aseptic reconstitution.
- Batch-specific third-party CoA documenting purity, identity, peptide content, and contaminant screening.
- Produced in GMP-aligned, ISO-compliant facilities.
- Optimized for research protocols exploring short-peptide effects on chondrocyte function, matrix dynamics, and epigenetic modulation in aging models.
Research-Referenced Attributes (Based on pre-clinical literature; no therapeutic claims)
- Pre-clinical studies in fibroblast and chondrocyte cultures demonstrate modulation of proliferation markers, suppression of pro-apoptotic pathways, and regulation of matrix metalloproteinase activity following exposure to short peptides including AED-like sequences (PMID: 27271332).
- In aging cell models, short bioregulatory peptides associate with upregulation of sirtuin family proteins (SIRT1/SIRT6), reduction of senescence-associated markers (p16INK4a, p21), and decreased inflammatory signaling (PMID: 32060528).
- Investigations in connective tissue and renal models show enhanced expression of longevity-related genes, reduced apoptotic signals, and support for tissue renewal processes in aged vs. young cell systems (PMID: 26016822).
- Broader reviews indicate ultrashort peptides influence chromatin structure, gene expression in tissue-specific manner, and cellular repair mechanisms in aging research contexts (PMID: 19830585; PMID: 24003726).
Why Researchers Choose Nationwide Peptides Cartalax
- Aligns with sequences featured in foundational bioregulator literature on connective tissue and cartilage models.
- Delivers full analytical transparency: HPLC/MS data, third-party CoA downloadable per batch.
- Ensures batch-to-batch reproducibility for demanding longitudinal and comparative pre-clinical work.
- Preferred by laboratories focused on aging biology, musculoskeletal research, and epigenetic regulation.
- Available in standard research vial sizes with transparent pricing and bulk options for extended protocols.
For Research Use Only. This product is intended strictly for in vitro and in vivo laboratory investigations by qualified researchers in controlled experimental environments. Statements regarding this product have not been evaluated by the FDA. It is not intended for human consumption, injection, diagnostic procedures, therapeutic use, or any purpose outside of controlled research.
Advance Your Cartilage & Connective Tissue Investigations
Select Cartalax tripeptide formulated for precision and reliability in pre-clinical bioregulation research. Current limited batches maintain verified ≥98% purity.
